Three Consecutive Guidance Cuts, a $151M Goodwill Write-Down, and SCDE Is Now a Loss-Making Drag — The BlueHalo Bet Is Failing in Real Time

Results vs. Consensus

Quality of Miss

• Revenue (-14 to -16% miss): The largest revenue miss since the FY25 Q3 wildfire quarter. SCDE collapsed 24% Q/Q ($129.3M vs. $170.9M), driven by the BADGER stop-work order and broader Space program adjustments. AxS declined 8% Q/Q ($278.7M vs. $301.6M), attributed to timing. Total revenue of $408M is the lowest quarterly figure since the BlueHalo close — and below both Q1's $454.7M and Q2's $472.5M. The sequential revenue trajectory is now declining, which is inconsistent with a company projecting "record Q4 revenue."
• EPS (-7 to -11% miss): The EPS miss was smaller than Q2's 45% whiff, suggesting some cost discipline. Non-GAAP EPS of $0.64 improved 45% Q/Q from $0.44 despite lower revenue — management appears to be managing expenses more tightly. However, the GAAP EPS of ($3.15) includes the $151.3M goodwill impairment ($2.95/share impact), creating the worst GAAP quarter in company history.
• EBITDA (flat Q/Q at $44.5M): Adjusted EBITDA essentially flat at $44.5M vs. $45.0M in Q2 — on 14% lower revenue. This implies margin expansion, which is genuinely positive. EBITDA margin improved from 9.5% to 10.9%. The improvement came from SCDE's loss narrowing (($1.7M) vs. estimated ($10.8M) in Q2) and AxS cost management. But the bar is low — EBITDA declining from $56.6M (Q1) to $44-45M (Q2-Q3) is not the trajectory of a business finding its footing.

Segment Performance

SCDE: The $151M Write-Down and What It Means

The $151.3M goodwill impairment in the Space reporting unit — triggered by a January 2026 stop-work order on the BADGER phased array antenna program for the Space Force's SCAR program — is the single most damaging event since BlueHalo closed. This isn't a mark-to-market adjustment; it's a permanent destruction of acquired value that acknowledges the Space business is worth materially less than what AeroVironment paid for it.

SCDE revenue collapsed 24% Q/Q to $129.3M, with EBITDA at ($1.7M). Across three quarters, SCDE has generated: $3.8M (Q1) + ~($10.8M) (Q2) + ($1.7M) (Q3) = approximately ($8.7M) in cumulative EBITDA on $469.6M in revenue. That's a segment EBITDA margin of -1.9% for its first 9 months. For context, this business was supposed to be the platform diversification that justified the $925M in acquisition debt.

Assessment: SCDE is a value trap within the combined company. The Space business lost a major program (BADGER), directed energy is early-stage, and the services component carries low margins. Unless SCDE can demonstrate consistent positive EBITDA in Q4 and beyond, the strategic rationale for BlueHalo — "multi-domain defense technology platform" — is undermined. The market has already begun repricing this: analysts maintained Buy ratings but cut PTs by $15-50, signaling growing discomfort with the SCDE drag.

AxS: First Sequential Decline

AxS revenue of $278.7M declined 8% Q/Q from $301.6M — the first sequential decline in the autonomous weapons segment during our coverage period. AxS EBITDA of $46.2M (16.6% margin) remained healthy but compressed from Q1's 18.5% and Q2's estimated ~18.5%. Management attributed the decline to "revenue timing" — the same language used to explain every prior miss. At some point, persistent "timing" issues become execution issues.

Assessment: The AxS decline is concerning because this is the profit engine. If AxS stabilizes at $280-300M/quarter with 16-18% EBITDA margins, the combined company can still generate $180-200M+ in annual AxS EBITDA. But a continued AxS decline — even if timing-driven — combined with SCDE's losses would make the FY EBITDA guide unreachable. Q4 AxS needs to be $320M+ with 18%+ margins to hit the low end of guidance.

Key Topics & Management Commentary

Overall Management Tone: Nawabi's messaging has become formulaic: "robust demand," "record backlog," "record fourth quarter revenue." These are the same phrases used after FY25 Q3's wildfire miss, after FY26 Q2's EPS whiff, and now after FY26 Q3's impairment. The credibility of forward-looking statements has eroded to the point where the market is discounting them — evidenced by the 10%+ selloff despite the "record Q4" promise. The tone hasn't adapted to the reality of three consecutive guidance cuts.

1. The Guidance Descent: From Raise to Ruin

Three cuts in three quarters (counting the raise-then-cut sequence) is a pattern that destroys investor trust. The Q1 raise was the catalyst for our Outperform upgrade in June; its complete reversal validates the Q2 downgrade to Hold and now necessitates a further downgrade. Management's forecasting ability for the combined company has proven unreliable — each quarter brings new surprises (ERP costs in Q2, BADGER stop-work in Q3) that weren't anticipated in the prior quarter's guide.

Assessment: Until management delivers a quarter that meets or beats guidance without subsequent revision, the Street should treat all forward estimates with a 10-15% haircut. The $2.93 EPS midpoint could easily become $2.50 if Q4 brings another unexpected headwind.

2. $4.6B in YTD Awards: The Demand Counter-Argument

Year-to-date awards of $4.6B (record) and funded backlog of $1.1B are the reason sell-side analysts maintained Buy ratings despite the miss. This demand signal is genuinely extraordinary — AVAV is booking orders at 3x+ its revenue run rate. The loitering munitions supercycle is real, Switchblade/Jump-20 demand is accelerating globally, and the defense budget environment favors autonomous systems.

"Demand for our unique solutions remains robust." — Wahid Nawabi, CEO

Assessment: The demand thesis is not in question. What's in question is whether this management team can convert demand into profit at the combined-company scale. Backlog without margin is just future low-quality revenue. The $4.6B in awards is a powerful long-term signal, but it doesn't fix the near-term SCDE margin problem, the guidance credibility gap, or the $727M debt load that requires EBITDA to service.

3. "Record Q4" — Should We Believe It This Time?

Management promised "record fourth quarter revenue" — the same language used after FY25 Q3. That time, they delivered ($275M record Q4). The FY26 math: 9-month revenue of $1.335B. Guide of $1.85-1.95B implies Q4 of $515-615M. At the midpoint ($565M), that would be a 38% sequential increase — aggressive but backed by $1.1B in funded backlog and seasonal DoD fiscal year-end spending patterns (DoD FY ends September 30, AVAV FY Q4 spans February-April, slightly ahead of but influenced by the DoD sprint).

Assessment: The "record Q4" is mathematically plausible given the backlog and seasonality. But the guide range is extremely wide ($515M-615M) — a 19% spread that reflects management's own uncertainty. A Q4 at the low end ($515M) would mean FY revenue of $1.85B and EBITDA likely at the bottom of the $265M range. That's a very different outcome than a $615M Q4 that would put FY at $1.95B and EBITDA at $285M. The stock's 10%+ selloff says the market is positioning for the low end.

Guidance & Outlook

Implied Q4: 9-month non-GAAP EPS: $1.40 ($0.32 + $0.44 + $0.64). FY guide midpoint: $2.93. Q4 needs: $1.53 — a 2.4x step-up from Q3's $0.64. 9-month EBITDA: $146.0M. FY guide midpoint: $275M. Q4 needs: $129M — a 2.9x step-up from Q3's $44.5M. These ramps are the largest implied in any quarter of our AVAV coverage and strain credulity given the trend of the prior three quarters.

What They're NOT Saying

1. BADGER program future: The $151M impairment was triggered by a stop-work order, but no clarity on whether the program is cancelled, restructured, or paused. The distinction matters enormously for SCDE's forward revenue.
2. Why the Q1 raise was wrong: Management raised EPS by 27% in September and has since cut it back to essentially the original level. No explanation for what changed — what did they see in Q1 that made them confident, and what happened since?
3. SCDE turnaround plan: Three quarters of loss-making SCDE operations and no articulated plan for getting the segment to positive margins. "Scaling manufacturing" is not a margin improvement plan.
4. Debt covenants: With $728M in debt and EBITDA tracking toward $275M (2.6x leverage), any further EBITDA deterioration could approach covenant thresholds. No discussion of covenant headroom was provided.

Market Reaction

• Pre-earnings: ~$227
• After-hours: -2.5% to ~$225
• Next-day pre-market: -9.2% to ~$201
• Total decline: ~10-12% over 24 hours
• Analysts: Needham maintained Buy ($450→$400), Citizens maintained Outperform ($400→$350), Baird maintained Outperform ($260→$235)

The 10-12% decline marks the third earnings selloff of 10%+ in the last five quarters (FY25 Q3: -18%, FY26 Q2: -12%, FY26 Q3: -10%). The pattern is now entrenched: the stock rallies between earnings on the demand narrative (backlog, bookings, LMS supercycle) then sells off when profitability disappoints. Notably, all three sell-side analysts maintained positive ratings — suggesting they view the demand story as worth owning through the integration mess. Their PT cuts ($15-50 each) acknowledge the margin reality without abandoning the structural thesis. The gap between sell-side conviction (Buy) and price action (-10%) reflects the disconnect between the 3-year view (demand wins) and the 3-month view (execution fails).

Street Perspective

Debate: Is This the FY25 Q3 Playbook Again?

Bull view: This is exactly FY25 Q3: a bad quarter driven by identifiable one-time events (wildfires then, BADGER stop-work now), followed by management promising a record Q4 — which they delivered last time. The $4.6B in YTD awards and $1.1B backlog provide the revenue to deliver again. Buy the selloff at $201, sell above $250 after Q4 beats.

Bear view: FY25 Q3 was a one-quarter aberration (wildfires). FY26 has been three consecutive quarters of disappointment — EBITDA declining, guidance cut three times, and now a $151M impairment. This isn't a one-time event; it's a pattern of a management team that can't execute at the combined-company scale. The "record Q4" promise now requires $129M in quarterly EBITDA — 2.9x Q3's level — which has never been achieved by this management team.

Our take: The bears have the stronger argument this time. FY25's playbook worked because the miss was genuinely one-time (wildfires) and the underlying business was healthy. This time, the miss is structural (SCDE margin failure, AxS declining, integration costs persisting) and compounded by a credibility gap (raise-then-triple-cut). The demand thesis provides a floor under the stock, but it doesn't justify paying 45-80x a declining EPS number. Patience is warranted, but from the sidelines, not from a long position.

Debate: Is the BlueHalo Acquisition Impaired Beyond the Write-Down?

Bull view: The $151M impairment is concentrated in the Space unit (BADGER), not in directed energy or EW. The core BlueHalo value — counter-UAS directed energy (LOCUST) and EW capabilities — remains intact. Space was always the weakest part of the portfolio; removing its goodwill is a cleaning exercise, not a thesis change.

Bear view: An impairment less than 12 months after close signals the due diligence missed something. SCDE has generated negative cumulative EBITDA across three quarters. The $925M in acquisition debt is being serviced by a segment that can't earn its cost of capital. If another unit requires impairment, the total write-down could approach $300M+ — a meaningful fraction of the total acquisition consideration.

Our take: The impairment is a real loss but not necessarily a thesis-killer for BlueHalo. The Space unit was always the riskiest piece. Directed energy (LOCUST, +5x pro-forma growth) and EW remain potentially high-value assets. But "potentially" is doing a lot of work — SCDE needs to demonstrate positive EBITDA in Q4 for the first time (excluding Q1's marginal $3.8M) to prove the remaining BlueHalo portfolio has value.

Model Update

Valuation: At ~$201-225 post-selloff (~$10-11B market cap), AVAV trades at 68-77x FY26E EPS ($2.93 mid) and 36-40x FY26E EBITDA ($275M mid). On an EPS basis, this is the most expensive the stock has looked across our coverage — and the EPS is declining. On EBITDA, 38x is premium for a defense company with declining margins and three consecutive guide cuts. We see fair value at $160-190 on current fundamentals (25-30x $275M EBITDA). At $200+, the stock is pricing in a turnaround that hasn't started.

Thesis Scorecard

Overall: The AVAV thesis has completed a full cycle over five quarters: from trough (FY25 Q3) to hope (FY25 Q4/FY26 Q1) to disappointment (FY26 Q2) to disillusionment (FY26 Q3). The demand thesis has only strengthened — $4.6B in awards is extraordinary — but the execution thesis has progressively deteriorated. BlueHalo's SCDE segment is value-destructive in its current form, management's forecasting credibility is shot, and the stock's premium valuation can't withstand another miss. The investment case now requires either (a) a much lower entry price ($160-180) that compensates for execution risk, or (b) demonstrated margin improvement that proves the combined company can convert its extraordinary demand into profit.

Action: Downgrade to Underperform from Hold. The accumulation of negative profitability signals overwhelms the demand positive. Target $160-190. Would reconsider at: (1) Q4 delivering $100M+ EBITDA proving the seasonal ramp, (2) SCDE reaching positive EBITDA for a sustained period, (3) stock pulling back to $160-180 where downside is more compensated, or (4) new management commentary providing credible synergy targets and a SCDE turnaround plan.